Ibrunat 140 mg Capsule
107.66$
73.21$
Ibrutinib 140 mg capsules are an innovative treatment option designed for adults battling chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), particularly those with specific genetic mutations that influence their condition. This oral medication works by inhibiting Bruton's tyrosine kinase, a crucial enzyme that promotes the survival and proliferation of cancerous cells, thereby helping to manage these blood cancers effectively. In addition to CLL and SLL, Ibrutinib is also indicated for adults diagnosed with Waldenström's macroglobulinemia (WM), a rare and aggressive form of non-Hodgkin lymphoma. While Ibrutinib can significantly improve outcomes, it's important for patients to be aware of potential side effects, including an increased risk of bleeding and infections. Regular monitoring by a healthcare professional is essential to ensure optimal use of this medication. If you are considering Ibrutinib 140 mg capsules, discuss with your doctor how this treatment can fit into your overall cancer management plan. With its targeted action, Ibrutinib represents a promising advancement in the fight against certain hematologic malignancies, offering hope to many patients.
الكمية
Active Pharmaceutical Ingredient
Uses
• Ibrutinib 140 mg capsule is primarily indicated for the treatment of adults with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). This medication targets specific pathways involved in cancer cell proliferation, helping to slow down the progression of the disease. Patients may experience improved disease management when using Ibrutinib 140 mg capsule as part of their treatment plan. It is often prescribed when other therapies have not been effective.
• The use of Ibrutinib 140 mg capsule extends to adults with CLL or SLL who have a deletion of the 17p chromosome. This specific genetic alteration can lead to a more aggressive form of the disease, making effective treatment essential. By inhibiting certain proteins, Ibrutinib 140 mg capsule helps to control the growth of malignant cells in these patients. Its targeted approach offers a vital option for those with this challenging diagnosis.
• Ibrutinib 140 mg capsule is also effective in managing Waldenström's macroglobulinemia (WM), a rare type of lymphoma. This medication works by disrupting the signals that promote cancer cell survival, thereby aiding in the reduction of disease symptoms. Patients with WM may find that Ibrutinib 140 mg capsule contributes to their overall treatment strategy. Its role in this context underscores its versatility in oncology.
• In addition to its uses in CLL, SLL, and WM, Ibrutinib 140 mg capsule is indicated for adults and children aged one year and older with chronic graft versus host disease (cGVHD) following failure of one or more lines of systemic therapy. This condition can be a significant complication after stem cell transplants, and Ibrutinib 140 mg capsule offers a targeted treatment option. By modulating the immune response, it helps improve outcomes for patients struggling with this challenging condition. Its application in cGVHD illustrates its broad therapeutic potential.
Benefits
Effective Treatment for CLL and SLL: Ibrunat 140 mg Capsule is proven to be effective in treating chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL), providing patients with an essential treatment option for these conditions.
Targets Specific Genetic Mutations: The Ibrunat Medicine is particularly beneficial for adults with CLL/SLL who have specific genetic mutations, offering a tailored approach to treatment.
Management of Waldenström's Macroglobulinemia: Ibrunat Capsule is effective in treating Waldenström's macroglobulinemia (WM), a rare type of non-Hodgkin lymphoma, improving outcomes for patients with this condition.
Chronic Graft-Versus-Host Disease (cGVHD): Ibrunat 140 mg is also approved for treating cGVHD in adults and children aged 1 year and older when other treatments have failed, providing an option for patients facing complications after stem cell transplants.
By effectively managing symptoms and slowing disease progression, Ibrunat Medicine can enhance the quality of life for patients living with CLL, SLL, WM, and cGVHD.
Side Effects
Ibrunat 140 mg Capsule can cause various adverse effects that can differ from one person to another. Some of the adverse effects of the drug are listed below.
Most Common Side Effects
• Tiredness
• Low red blood cell count (anaemia)
• Bruising
• Diarrhea
• Muscle, bone, and joint pain
• Fever
Common Side Effects
• Muscle spasms
• Mouth sores (stomatitis)
• Bleeding
• Nausea
• Stomach pain
• Pneumonia
• Headache
How To Use
To take or give Ibrunat 140 mg Capsule, follow your doctor's instructions carefully. This Ibrutinib Capsule 140 mg is usually taken once a day with a full glass of water, either with or without food. Swallow the capsules whole; do not crush, chew, or break them. Keep to a schedule and try to take your doses at the same time each day. If you miss a dose, take it as soon as possible on the same day. Do not take extra doses to make up for a missed dose. Avoid grapefruit or grapefruit juice while you are taking Ibrunat Capsule, as it may interfere with the action of the medicine. Keep the medicine in a safe place away from children, and do not give it to anyone else, even if they have similar symptoms. If you have any questions or experience side effects, contact your doctor for advice.
Safety Advice
• Alcohol: It is not known whether it is safe to drink alcohol with Ibrunat 140 mg. Please consult your doctor.
• Kidney: Ibrunat 140 mg Capsule should be used with caution in patients with kidney disease. The dose of Ibrunat Capsule may need to be adjusted. Please consult your doctor.
• Breastfeeding: Ibrunat Medicine should be used with caution during breast-feeding. Breastfeeding should be continued until the mother's treatment is complete and the drug has been eliminated from her body.
• Liver: Ibrunat 140 mg Capsule should be used with caution in patients with liver disease. The dose of Ibrunat 140 mg may need to be adjusted. Please consult your doctor.
• Pregnancy: Ibrutinib Capsule 140 mg is not safe to use during pregnancy, as there is clear evidence of a risk to the developing baby. However, the doctor may rarely prescribe it in certain life-threatening situations where the benefits outweigh the potential risks. Please consult your doctor.
• Driving: Ibrunat Capsule can cause side effects that may affect your ability to drive a car.